IL6 and ovarian carcinoma: Researchers discovered that elevated A2B receptor expression in ovarian cancer cells senses adenosine signals, triggering the IL-6-STAT3 signaling cascade, which contributes to tumor cell survival, proliferation, migration, and reduced sensitivity to the PARP inhibitor olaparib [39].